Filing Flows › Atrium Therapeutics (RNA) › Q1 2026 › vs Q1 2025
Atrium Therapeutics (RNA) Q1 2026 vs Q1 2025 (year over year)
Atrium Therapeutics's revenue rose $18.1M (12×) from $1.6M in Q1 2025 to $19.6M in Q1 2026.
Atrium Therapeutics, Q1 2026: revenue $19.6M (12× year over year), operating margin -88.0%, net loss $16.6M, operating cash flow −$31.1M. The chart draws each line against Q1 2025, the increases inside each band.
Every line
| Line | Q1 2026 | Q1 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $19.6M | $1.6M | $18.1M | 12× |
| Other income, net | $647K | $3K | $644K | 216× |
| Net loss | $16.6M | $7.4M | $9.2M | +123% |
| Costs & expenses | $36.9M | $9.0M | $27.9M | +309% |
| Operating costs | $36.9M | $9.0M | $27.9M | +309% |
| Research & development | $16.7M | $6.9M | $9.7M | +140% |
| General & admin | $20.3M | $2.1M | $18.2M | +870% |
| Operating cash sources | $43.5M | $12.4M | $31.1M | +252% |
| Depreciation | $151K | $53K | $98K | +185% |
| Share-based compensation | $12.2M | $1.2M | $11.0M | +909% |
| Cash used in operations | $31.1M | $11.1M | $20.0M | +180% |
| Net loss absorbed | $16.6M | $7.4M | $9.2M | +123% |
| Working capital & other | $26.9M | $4.9M | $22.0M | +447% |
Questions
How much did Atrium Therapeutics's revenue grow year over year in Q1 2026?
Atrium Therapeutics's revenue rose $18.1M (12×) from $1.6M in Q1 2025 to $19.6M in Q1 2026.